Thrombosis Choice and Duration of Anticoagulation



Disclosure

Faculty: Ben Schwartzentruber, UBC clinical instructor

Relationship with financial sponsors:

- No relationship with industry (speaking, honoraria, etc.)
- I am participating in the SSC funded Physician Quality Improvement curriculum focusing on thrombosis care, for which I receive sessional funding
- I am one of 4 internists participating in a pilot DVT pathway at RJH, a hospital funded clinic, and I get FFS for seeing patients there

Mitigating Bias

Faculty: Ben Schwartzentruber, UBC clinical instructor

Any recommendations I make are concordant with current guidelines or the pattern of practice of my thrombosis colleagues in areas not directly addressed by guidelines (Thrombosis Canada, ACCP, ISTH)



Choice of Anticoagulant



Choice of Anticoagulant

DOACs should be first line for the majority of patients

- in the major VTE trials, DOACs (esp. FXa inhibitors) have at least equal efficacy, and consistently lower bleeding risk compared to VKA
- RR for major bleed 0.61
- no monitoring, no bridging

Which DOAC?

- apixaban is generic, and no SA needed as of this month
- rivaroxaban is once daily (after 3/52)

Drug Interactions

PGP and CYP 3A4

- inducers (more clotting): rifampin, phenytoin, carbamazepine, some antiandrogens (*e.g.*, apalutamide)
- inhibitors (more bleeding): diltiazem, naproxen, -azoles, HIV protease inhibitors

PEARL: LMWH interacts with NOTHING, and has at least as good safety and efficacy as anything given orally

Choice of Anticoagulant

Special cases:

- rivaroxaban a/w more heavy menstrual bleeding than apixaban
- dabigatran/edoxaban may be options if there are drug interactions
 - e.g., antiretroviral therapy
- LMWH preferred for anyone with GU and luminal GI malignancies
- limited DOAC data in patient with BMI > 40 or weight > 150 kg
 - guidelines suggest DOACs for all body weights based on retrospective data
 - more evidence for rivaroxaban than apixaban
- APLA: VKA

What about reversibility?



I don't care that warfarin has an antidote

• it is MUCH better not to have a major bleed in the first place

The DOACs also have studied antidotes (andexanet alfa, idaracizumab)
trials pharmacokinetic, drugs expensive and unavailable

Inpatients: same is true for UFH vs. LMWH!

• bleeding higher, HIT more frequent, more supra-, subtherapeutic

Dosing for VTE

DOACs:

- Apixaban 10 mg BID x 7 days then 5 mg BID for acute phase
- Rivaroxaban 15 mg BID x 21 days then 20 mg daily
- Dabigatran (LMWH x 5) then 150 mg BID
- Edoxaban (LMWH x 5) 60 mg daily or 30 mg daily (wt. > 60 kg)

Note: NO dose adjustment for renal impairment has been studied, unlike atrial fibrillation

- apix studied down to CrCl < 25; in practice CrCl >15
- riva CrCl 30

Dosing for VTE

LMWH

- dalteparin 200 units / kg round to nearest prefill
- tinzaparin 175 units / kg down to CrCl 20
- enoxaparin 1 mg / kg BID or 1.5 mg / kg daily (equivalent)

Warfarin

who knows???

Duration of Anticoagulation





Why I Treat VTE

Treat acute symptoms Prevent chronic symptoms (PTS, CTED/CTEPH) Prevent recurrent VTE Prevent death

As long as I am not making things worse with bleeding
major bleeding is a contraindication to anticoagulation!

Acute Phase

"Three to six months"

- the smaller and more provoked, the shorter I treat acutely
- the larger, more symptomatic, and less provoked, the longer I treat

Special cases:

pregnancy - until 6 weeks postpartum for all

Note: AC should only be interrupted for emergencies in acute phase • *e.g.,* biopsy for newly detected cancer, not dental stuff

Long Term Prevention

For people with high risk of recurrence, and low risk of bleed, may continue "long term" at reduced dose

- both apixaban 2.5 mg BID and rivaroxaban 10 mg daily studied
- studies lasted 1 year, showed no difference in efficacy or safety


Young, active: can interrupt for a weekend of mountain biking or mixed martial arts!

Long Term Prevention

Does everyone with unprovoked VTE need to be anticoagulated forever?

Risk of recurrent [fatal] VTE after initial treatment (Khan et al. 2019)

- year 1: 10.3% [0.4%]
- year 2: 16.0% [0.7%]
- year 5: 25.2% [1.0%]
- year 10: 36.1% [1.5%]
- treatment reduces recurrence risk by ~80%
- men have 1.4 x recurrence risk as women



Long Term Prevention

Does everyone with unprovoked VTE need to be anticoagulated forever?

Risk of major bleeding [fatal] on treatment (Khan et al. 2021):

- VKA year 1: 2.00% [0.18%] DOAC: 1.20% [0.11]
- VKA year 2: 3.6% [0.4%]
- VKA year 5: 6.3% [1.0%]
- bleeding risk: age > 65, CrCl < 50, pts on antiplatelet, anemia, female
- if 2+ RFs for bleeding, consider stopping anticoagulation

Interruption

Bleeding Risk:

https://thrombosiscanada.ca/wp-uploads/uploads/2019/01/Risk-of-Periop-Bleeding-e1547756533302.png

DOAC	Surgical Procedure- Associated Bleeding Risk	Preoperative DOAC Interruption Schedule						Postoperative DOAC Resumption Schedule			
		Day -5	Day -4	Day -3	Day -2	Day -1		Day +1	Day +2	Day +3	Day +4
Apixaban	High	-					DOAC)				
	Low						e (No E				>
Dabigatran etexilate (CrCl ≥50 mL/min)	High			>			ocedure		_		
	Low						cal Pro				
Dabigatran etexilate (CrCl <50 mL/min) ^a	High	>					Day of Surgical Procedure (No DOAC)				
	Low						Day o				
Rivaroxaban	High	-									
	Low										>

When to Workup Thrombophilia

Don't! Recurrence risk comes from provoking event (or lack thereof) But for unprovoked VTE, please update malignancy screening

 case detection by history, physical, labs, +/- imaging for covert malignancy (SOME trial, 2015)

Exceptions:

- I send antiphospholipid testing for unprovoked VTE < age 60
- Patient who could become pregnant or who have 1st degree relatives who could (would affect prophylaxis in pregnancy)

When to Refer

Whenever you need help with decision-making or the patient needs to hear another doctor agree with you!

- I am happy to see these referrals at UMAC
- Pacific Hematology is also happy to see these patients



Thank You!

Questions?

Ben Schwartzentruber, MD, FRCPC General Internal Medicine bennet.schwartzentruber@islandhealth.ca



January 26, 2023